Clinical Trials Browser

Phase 2 × NIH × obinutuzumab × Clear all

NCT03269669 2026-03-19

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Phase 2 Active not recruiting

Lymphoma, Follicular

NCT07003295 2026-03-19

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

Phase 2 Recruiting

Lymphoma, Mantle-Cell